We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.52 | 0.41% | 127.52 | 364 | 09:23:26 |
From Apr 2019 to Apr 2024
By Dave Sebastian
Moderna Inc. said it has regained rights to the respiratory syncytial virus vaccine from Merck & Co. Inc., allowing the company to develop the vaccine in adults.
The vaccine, named mRNA-1172 and known as MSD outside the U.S. and Canada, uses a Merck lipid nanoparticle and entered early-stage development last year. Merck will complete the phase-one study, Moderna said.
RSV is a pathogen that leads to cold-like symptoms, according to the Centers for Disease Control and Prevention. It could cause more severe infections such as bronchiolitis and pneumonia, the CDC said.
Moderna also said it is starting dosing in the phase one study of mRNA-1345, its solely owned RSV vaccine candidate. The dosing will start in adults, it said.
Merck's RSV efforts will go toward its antibody program that is in phase-two development, Moderna said.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
October 08, 2020 07:41 ET (11:41 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
